Background: Lenalidomide (LEN), an immunomodulatory drug (IMiD), is currently used for treatment of multiple myeloma (MM). LEN potentiates T cell and natural killer cell functions. However, the cellular and molecular mechanisms underlying the immunomodulatory effects of LEN remain unclear. We focused on the effects of LEN on human plasmacytoid dendritic cells (pDCs), which are the major source of interferon (IFN)-α in the blood and play a central role in innate immune responses. Results: We found that bortezomib, a proteasome inhibitor used to treat MM, killed pDCs but that 0.1-3 μM LEN (covering clinical plasma concentration range) did not affect pDC survival or CD86 expression. Bortezomib inhibited pDC-derived IFN-α production in a dosedependent fashion, but 0.1-3 µM LEN sustained pDC-derived IFN-α production when stimulated with an optimal concentration of CpG-ODN 2216 (3 μM). In pDCs stimulated with a low concentration of CpG-ODN (0.1 μM), LEN enhanced IFN-α production. These results indicated that LEN, when used at a clinically relevant concentration, can potentially enhance IFN-α production by pDCs. Conclusion: Collectively, our findings unveiled a novel target of LEN and extend the repertoire of the drug's known immunomodulatory effects. These effects may explain the low incidence of herpes zoster viral infection observed during LEN treatment compared with bortezomib treatment. LEN may function as an IMiD affecting a wide array of immune cells, including pDCs, leading to amplification of a positive immune axis able to eliminate MM cells.
Introduction
Lenalidomide (LEN) and pomalidomide (POM) are classified as an immunomodulatory drugs (IMiDs) with both direct tumoricidal and immunomodulatory effects. Both drugs are used in the treatment of multiple myeloma (MM). LEN is an integral backbone drug for MM. At present, the standard of care for patients with newly diagnosed or relapsed/refractory MM is to administer LEN combined with proteasome inhibitors or antibody-drugs. Continuous treatment with LEN until diseases progression confers a survival benefit for MM patients. 1 Recent studies have elucidated the diversity of immune cells targeted by LEN. LEN promotes the proliferation of some immune effector cells in vivo. The total percentage of proliferating S-phase CD4 + T cells, CD8 + T cells, and natural killer smoldering MM patients. 2 In addition to this quantitative enhancement, several studies have shown that LEN induces qualitative activation of several immune cells. For instance, LEN augments NK cell cytotoxicity and cytotoxic lymphocyte (CTL) activity, [3] [4] [5] [6] [7] [8] and inhibits the proliferation and function of Treg cells. 9, 10 PD-L1 and PD-1 expression are increased in MM cells and immune effector cells (such as CTLs and NK cells), respectively, in MM patients. 11, 12 In addition to the enhancing effect of LEN on immune effectors, LEN can downregulate PD-L1 on primary MM cells and PD-1 on NK cells and CTL cells of MM patients, leading to enhanced immune responses induced by immune checkpoint blockade. 11, 12 Thus, LEN has a potent and complex immunostimulatory effect, facilitating the attack of MM cells by activated immune effectors. This function of LEN is relevant to the treatment of MM patients under immune dysfunction. However, the cellular and molecular mechanisms underlying the immunomodulatory effects of LEN remain unclear.
A series of analyses have clarified the functional plasticity of dendritic cells (DCs) in inducing T-helper (Th)1 or Th2 responses. DCs, as cellular commanders of the immune cascade, are pivotal in orchestrating both innate and acquired immune responses. Though they make up only a small fraction of peripheral blood mononuclear cells (PBMCs), plasmacytoid DCs (pDCs) represent a major source of type I interferons (IFNs) amongst PBMCs and lymphoid tissues in both humans and mice. 13, 14 Human pDCs produce less IL-12 but dedicate a large proportion of their transcriptional machinery to producing type I IFNs. pDCs play a central role in the innate antiviral immune response through their ability to robustly produce type I IFNs upon viral infection. 15 Type I IFNs can enhance immune effector cells such as T cells, B cells, monocytes, and NK cells [16] [17] [18] pDCs respond to viral infection through their selective expression of Toll-like receptor (TLR)7 and TLR9, which sense viral RNA and DNA, respectively, within early endosomes.
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Although there is evidence demonstrating the immunomodulatory effects of LEN on mouse conventional DCs, 8, 20 only a few reports have examined its effects on human DC subsets. We studied the effect of LEN on the type I IFN-producing capacity of human pDCs to elucidate the immunopotentiating activity of LEN in regards to the total immune system. We show that LEN has a novel function in sustaining and enhancing the IFN-α production by human pDCs without affecting their survival. These data suggest that LEN functions as a positive immunomodulator, modulating the initial phases of the immune cascade.
Materials and methods

Media and reagents
RPMI-1640 supplemented with 2 mM L-glutamine, 100 U/ mL penicillin, 100 ng/mL streptomycin and 10% heat-inactivated fetal bovine serum (Biosource International) was used for all cell culture experiments. For human cell stimulation, we used 0.1-3 μM CpG-ODN 2216 (Invivogen). LEN (SelleckChem), POM (Sigma), and bortezomib (LC Laboratories) were dissolved in 100% dimethyl sulfoxide (DMSO). Diluted DMSO was used as a vehicle control.
Cell isolation and culture
Human blood DCs were isolated from healthy adult volunteers as previously described. 21 
Analysis of cells
Human pDCs were stained with FITC-labeled CD86 (2331: BD Biosciences) and then analyzed using a FACScalibur ® (BD Biosciences). Dead cells were excluded based on sideand forward-scatter characteristics. Cells were washed with phosphate-buffered saline containing 2 mM EDTA, and viable cells were counted in triplicate using trypan blue exclusion. Viable cells were also evaluated as annexin Vnegative fractions using an annexin V-FITC Apoptosis Detection kit (Sigma-Aldrich). Production of IFN-α in culture supernatants after 24 h was assessed by ELISA (PBL Biomedical Laboratories).
Statistical analysis
Data were analyzed using the student's t-test. Values of p<0.05 were considered statistically significant. Data analysis was carried out using GraphPad Prism (GraphPad Software).
Results
Clinical concentrations of LEN do not affect human pDC survival and maturation
Since presence of CpG-ODN 2216, although pDCs were susceptible to the cytotoxic effects of bortezomib. We confirmed this finding using trypan-blue exclusion of the dead cells (data not shown). We next investigated the effects of LEN on pDC maturation. pDCs treated with 0.1-3 μM of LEN showed no change in CD86 expression in response to CpG-ODN 2216 (Figure 2A ). pDCs exposed to 3-300 nM of bortezomib (covering the clinical in vivo plasma concentration range following intravenous bortezomib administration 24 ) showed greatly reduced viability and CD86 expression after exposure to CpG-ODN 2216 (Figures 1 and 2A) . Consistent with CD86 expression, CpG-prestimulated pDCs and LEN-conditioned CpG-prestimulated pDCs induced expansion of CD4 + T cells comparably. By contrast, bortezomib-conditioned CpG-prestimulated pDCs showed an impaired ability to expand CD4 + T cells ( Figure 2B ).
Frequency of pDCs was not decreased in MM patients treated with LEN
To confirm that LEN was not cytotoxic against pDCs in the MM patients after treatment, we next investigated the frequency of pDCs in the PB of MM patients before and after LEN administration. pDCs were detected using flow cytometry as BDCA-2-positive population in the lineage (CD3, CD14, CD15, CD16, CD19, and CD56)-negative, CD11c-negative, and CD4-positive fraction ( Figure 3A ). We examined PB Exposure to clinical concentrations of LEN sustained and potentially enhanced IFN-α production by human pDCs
We next examined the immunomodulatory properties of LEN toward human PBMCs and purified pDCs. We measured IFN-α production by human PBMCs and purified pDCs, which are the major source of type I IFNs, 14 bortezomib act directly on pDCs. As shown in Figure 5A , bortezomib dose-dependently inhibited pDC-derived IFN-α production, in line with a previous report. 25 However, exposure to 0.01-3 μM of LEN resulted in sustained IFN-α production in pDC cultures when stimulated with an optimal concentration of CpG-ODN 2216 (3 μM) ( Figure  5B ). To address the possibility that LEN enhanced IFN-α production by pDCs that could not be observed because of exhaustion following maximal CpG-ODN 2216 stimulation, we used a suboptimal concentration of CpG-ODN 2216 to stimulate pDCs. Upon stimulation with a suboptimal concentration of CpG-ODN 2216 (0.1 µM), 1 µM of LEN enhanced pDC-derived IFN-α production (185% of vehicle control culture; p=0.023) ( Figure 5C ). These results indicated that exposure to a clinical concentration of LEN sustained and potentially enhanced, IFN-α production by pDCs in response to weak CpG stimulation. POM is another IMiD 26 and the clinical peak plasma concentration following oral administration of 4 mg POM is 0.27 μM (75 ng/mL). 27 We found that 0.3 μM POM also did not affect human pDC survival and sustained IFN-α production by pDCs in response to CpG-ODN 2216 (3 μM) ( Figure S1 ). This result suggested that POM may have a similar immunomodulatory effect on pDC function.
Discussion
MM involves an element of immune dysfunction, 12, 28, 29 including an increased number of Tregs, which is associated with poor clinical outcomes. 30, 31 Therefore, immunotherapies or drugs that can improve immune status are considered effective therapeutic strategies, making IMiDs backbone drugs for MM. Although LEN was the first anti-MM drug with an immunomodulatory effect, its mechanism of action had been elusive. The present study showed that LEN potentially amplified the ability of pDCs to produce endogenous IFN-α and elucidated an additional cellular target of LEN. Our results provide new insight into a possible mechanism through which LEN operates as a pleiotropic immunomodulator. In our study, LEN significantly enhanced IFN-α production by pDCs stimulated with the low concentrations of CpG-ODN but not with an optimal high concentration. Although pDCs rapidly produce vast amounts of type I IFNs following stimulation by viruses or CpG-ODN, 13 pDCs are incapable of mounting a secondary type I IFN response to further stimulation. 15 In this context, pDCs do not retain sufficient capacity to further produce type I IFNs by the maximal response to optimal stimulation. However, LEN was able to promote the residual capacity of pDCs to produce IFN-α when stimulated with a low concentration of CpG-ODN in our study. Type I IFNs directly inhibit the proliferation of tumors and virus-infected cells, and are known to play a central role in antitumor and antiviral immune responses. 32 Furthermore, type I IFNs directly activate diverse immune cell types, such as NK cells, B cells, monocytes, antigenpresenting DCs, and T cells. [16] [17] [18] Type I IFNs are able to enhance cellular activities, such as the ability of NK cells to kill target cells, monocyte function, and the differentiation of monocytes into DCs. [33] [34] [35] Moreover, type I IFNs suppress generation of Treg cells. 36 These functions of type I IFNs might work synergistically to mediate the effect of LEN in enhancing cellular immunity.
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Furthermore, type I IFNs are directly involved in the maturation and sustainment of conventional DCs, 37 and also affect the ability of myeloid DCs to secrete IL12p70. [46] [47] [48] No decrease in blood pDCs was observed in MM patients following administration of LEN in our study. This finding was further supported by the result that LEN did not adversely affect pDC survival and maturation in vitro. No conclusion could be reached regarding the blood DC numbers in MM patients. One report showed a decreased number of blood pDCs in MM patients compared with healthy donors, 49 whereas two other studies found that blood pDC numbers in MM patients were nearly identical to those of normal donors. 28, 50 We have previously reported that blood pDC numbers were unaltered in patients with tuberculosis 51 and Sjögren syndrome, 52 but decreased in patients with sarcoidosis 53 and acute graft-versushost disease. 54 Although only a small number of patients were included in the current study, we also found no significant difference in blood pDC numbers between healthy donors and MM patients. It is possible that pDCs in MM patients, within the normal numeric range, can function better when LEN is administered. Continuous treatment with low dose LEN as a maintenance therapy contributes to better survival in MM patients. 55, 56 The clinical pharmacokinetics of LEN show a gentle curve from the peak plasma concentration: 10 mg of LEN (administered orally) to MM patients results in an approximate clinical peak plasma concentration of 1.2 µM. 23 Our results showed that, even at a low concentration (0.1-1.0 μM, equivalent to the clinical plasma concentration range resulting from oral administration of 10 mg LEN), LEN sustained IFN-α production by PBMCs and pDCs. This finding suggested that low dose LEN (ie, 10 mg oral administration) could function as an immunostimulator during maintenance therapy.
Conclusions
The results of our study showed that LEN sustained and potentially enhanced the ability of pDCs to produce type I IFNs without affecting their survival and maturation. LEN orchestrates the activities of a wide variety of both innate and adaptive immune cells, leading to amplification of a positive immune axis for eliminating MM cells. Our findings unveiled one part of the mechanism responsible for the immunomodulatory functions of LEN in the treatment of MM. In addition, our data provide a plausible explanation for the observed benefit of LEN in boosting immune defense against herpes zoster virus.
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